RecruitingPhase 1NCT07661108

A Clinical Study of MK-8527 in Healthy Participants (MK-8527-021)

An Open-label, Phase 1 Study to Individually Characterize the Food Effect, the Drug-Drug Interaction Effect of OAT Inhibition, and the Drug-Drug Interaction Effect of P-glycoprotein Inhibition on the Pharmacokinetics of MK-8527 in Healthy Adult Participants

Sponsor

Merck Sharp & Dohme LLC

Enrollment

44 participants

Start Date

Jun 30, 2026

Study Type

INTERVENTIONAL

Conditions

Healthy

Summary

Researchers are studying a medicine called MK-8527 to learn how it behaves in the body of healthy adults. The goal of this study is to learn about the effect of MK-8527 when it is taken with food or with other medicines. Researchers also want to learn about the safety of MK-8527 and if people tolerate it. Tolerate means participants will receive treatment in the trial unless they need to stop it due to health problems.

Eligibility

Min Age: 18 YearsMax Age: 55 Years

Inclusion Criteria2

Be in good health
Has a body mass index (BMI) between 18 and 32 kg/m\^2, inclusive

Exclusion Criteria5

Has an estimated glomerular filtration rate (eGFR) ≤90 mL/min/1.73 m\^2
Has a history of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
Has a history of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy and hernia repair are allowed)
Has a history of cancer (malignancy)
Is taking any medication that contains emtricitabine (FTC) or lamivudine (3TC)

Interested in this trial?

Get notified about updates and connect with the research team.